A retrospective study of disproportionality analysis signals between proprotein convertase subtilisin/kexin 9 inhibitor use and respiratory, thoracic, and mediastinal disorders. (PubMed, Medicine (Baltimore)) - Sep 2, 2026 - "The median time to onset for adverse event reports was 7.5 days (interquartile range = 0.5-77.5 days); the median time to onset for reports related to alirocumab was 14.5 days (interquartile range = 1.5-100.5 days), while for evolocumab it was only 6.5 days (interquartile range = 0.5-70.5 days). Among these, rhinorrhea, cough, oropharyngeal pain, nasal congestion, and dysphonia were the most frequently reported preferred terms (PTs). The results of this study indicate the presence of a disproportionate signal of RTMD adverse events associated with PCSK9i in the FAERS database; however, this merely suggests that such events warrant further attention in reports related to PCSK9i and does not establish a causal relationship between the 2."
Journal • Retrospective data • Cough • Dysphonia • Pain • Respiratory Diseases
|